Quantum Biopharma (QNTM) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Quantum Biopharma (NASDAQ:QNTM) is set to release its earnings on August 13th, with analysts predicting a loss of ($0.17) per share.
• In its last earnings report, the company reported a significantly larger loss of ($1.41) per share, missing expectations by ($1.04).
• The stock of Quantum Biopharma has fallen 11.6% recently, with its market cap currently at $71.50 million.

Quantum Biopharma (NASDAQ:QNTM - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Quantum Biopharma to post earnings of ($0.17) per share and revenue of $2.89 million for the quarter.

Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($3.23) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($3.06). On average, analysts expect Quantum Biopharma to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Quantum Biopharma Stock Up 12.3%

Shares of NASDAQ:QNTM traded up $3.20 during trading on Friday, reaching $29.21. 215,475 shares of the company's stock traded hands, compared to its average volume of 157,062. Quantum Biopharma has a fifty-two week low of $2.70 and a fifty-two week high of $38.25. The firm has a market cap of $85.00 million, a PE ratio of -2.08 and a beta of 0.71. The company has a 50-day simple moving average of $21.53 and a 200-day simple moving average of $12.24.

Analyst Ratings Changes

A number of research firms have weighed in on QNTM. Singular Research raised shares of Quantum Biopharma to a "moderate buy" rating in a research note on Wednesday, June 18th. Wall Street Zen upgraded Quantum Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.